[
    [
        {
            "time": "2021-01-01",
            "original_text": "复星医药：积极推进新型冠状病毒mRNA疫苗上市进展",
            "features": {
                "keywords": [
                    "复星医药",
                    "新型冠状病毒",
                    "mRNA疫苗",
                    "上市进展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：积极推进新型冠状病毒mRNA疫苗上市进展",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-01",
            "original_text": "复星医药(02196)聘请中金公司担任非公开发行A股股票工作的保荐机构",
            "features": {
                "keywords": [
                    "复星医药",
                    "中金公司",
                    "非公开发行",
                    "A股股票",
                    "保荐机构"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196)聘请中金公司担任非公开发行A股股票工作的保荐机构",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-01",
            "original_text": "复星医药(02196.HK)拟变更保荐机构及保荐代表人",
            "features": {
                "keywords": [
                    "复星医药",
                    "保荐机构",
                    "变更",
                    "保荐代表人"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "制药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)拟变更保荐机构及保荐代表人",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-01",
            "original_text": "复星医药(02196.HK)参与设立的投资基金完成私募投资基金备案",
            "features": {
                "keywords": [
                    "复星医药",
                    "投资基金",
                    "私募投资基金",
                    "备案"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)参与设立的投资基金完成私募投资基金备案",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-01",
            "original_text": "【异动股】复星医药(02196-HK)跌3.22%",
            "features": {
                "keywords": [
                    "复星医药",
                    "异动股",
                    "下跌",
                    "3.22%"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【异动股】复星医药(02196-HK)跌3.22%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-01-01",
            "original_text": "2021年，创新转型将成为传统药企发展重点",
            "features": {
                "keywords": [
                    "2021年",
                    "创新转型",
                    "传统药企",
                    "发展重点"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药",
                    "创新"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2021年，创新转型将成为传统药企发展重点",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]